Thermo Fisher Scientific Inc. is helping proteomics researchers increase productivity and free up time for more value-added activities when generating high quality samples for analysis, using a new automated sample preparation system that integrates within any LC-MS workflow.

Thermo Fisher Scientific Inc. is providing proteomics and biopharmaceutical laboratories working in drug discovery and R&D applications with an innovative mass spectrometry solution that, for the first time, unlocks the ability to clearly decipher complex mixtures of large macromolecules.

Thermo Fisher Scientific announces the winners of the 2022 Thermo Scientific Tandem Mass Tag (TMT) Research Award.

Thermo Fisher Scientific Inc. and TransMIT GmbH Center for Mass Spectrometric Developments have announced a co-marketing agreement to promote the use of a mass spectrometry imaging (MSI) platform for spatial multi-omics applications in pharma and clinical labs.

Thermo Fisher Scientific Inc. is showcasing new instruments, workflows, software and industry collaborations that enable customers to generate new analytical insights and accelerate next generation vaccine and therapy development.

Dotmatics today announced the addition of Larry Samuelson as Chief Legal Officer and Neil Frye as Chief People Officer.

Today at the Advances in Genome Biology and Technology (AGBT) Conference, DNA Script announced the launch of the industry’s first solution to enable same-day turnaround for custom q/dPCR assays with a new generation of kits for the SYNTAX System to print both primers and probes in hours.

seqWell, a global provider of genomic library workflow solutions including the plexWell™ next-generation sequencing (NGS) multiplexing technology, today announced a partnership with Element Biosciences Inc., developer of the Element AVITI™ System.

EKF Diagnostics, the global in vitro diagnostics company, announces the launch of its new EKF Link digital connectivity solution for the secure management of point-of-care (POC) analyzers and associated data on one centralized platform.

AMSBIO announce a new range of high-quality bispecific antibodies (BsAbs) and trispecific antibodies (TsAbs) that can used to provide enhanced cancer therapeutic efficacy and/or safety compared to what can be achieved with conventional monospecific antibodies.